30Oct
[Video] I Wish I Knew What I Know Now: Conversations with AGG on FDA Issues - Key Due Diligence Issues to Consider When Acquiring or Investing in Life Sciences Companies or Products
AGG is pleased to present the second episode in a podcast series titled, “I Wish I Know What I Know Now: Conversations with AGG on FDA Issues,” covering key due diligence issues to consider when acquiring or investing in life science companies or products. In this episode, AGG partner Alan G. Minsk and Brian A. Teras provides an overview of the diligence process, potential red flags, common mistakes, and other factors to consider during the due diligence process. Each month, we'll release a...
By:
Arnall Golden Gregory LLP
Related
On August 15, 2019, the Office of Federal Compliance Contract Programs (OFCCP) proposed a new rule b...
Read More >
The Securities and Exchange Commission ("SEC" or "Commission") recently proposed a number of changes...
Read More >
In light of several recent immigration-related developments, we are providing an update on the follo...
Read More >
Among various other disruptions and turbulence that COVID-19 has brought to the construction industr...
Read More >
It's the end of the year and while everyone is busy, employers in California should be aware of new ...
Read More >
On March 1, 2020, United States Citizenship and Immigration Services (“USCIS”) will be implementin...
Read More >